Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A

Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects

(2012) M. Boyce et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Unusually aggressive type 1 gastric carcinoid

(2012) Matilde Pia Spampatti et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Development of type I gastric carcinoid in patients with chronic atrophic gastritis

(2011) L. Vannella et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Type I Gastric Carcinoids: A Prospective Study on Endoscopic Management and Recurrence Rate

(2011) Elettra Merola et al.   NEUROENDOCRINOLOGY

Mechanism of Acid Hypersecretion Post Curative Gastrinoma Resection

(2010) Jeremiah V. Ojeaburu et al.   DIGESTIVE DISEASES AND SCIENCES

Laparoscopic Antrectomy for the Treatment of Type I Gastric Carcinoid Tumors

(2010) Junko Ozao-Choy et al.   JOURNAL OF SURGICAL RESEARCH

The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development

(2010) M Kidd et al.   REGULATORY PEPTIDES

Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids

(2010) Constantin S. Jianu et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Neuroendocrine tumor epidemiology

(2008) Oyvind Hauso et al.   CANCER

Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours

(2008) Simona Grozinsky-Glasberg et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition

(2007) Reidar Fossmark et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY